Study to examine vitamin D, omega-3 supplements
This article was originally published in The Tan Sheet
The Vitamin D and Omega-3 Trial - VITAL - will measure the supplements' preventive effects on cancer, heart disease and stroke in 20,000 participants, making it the largest randomized trial for vitamin D and omega-3 fatty acids. Brigham and Women's Hospital, an affiliate of Harvard Medical School, seeks to enroll women older than 65 and men older than 60 in the five-year study, which will include examinations of how the supplements affect cognitive function, vision disorders and diabetes, the hospital said. BWH Chief of Preventive Medicine JoAnn Manson said June 23 that "these low-cost supplements have the potential of tremendously reducing the burden of chronic disease." Previous economic analysis found omega-3 and vitamin D plus calcium supplementation could save billions in hospitalization costs (1"The Tan Sheet" Sept. 29, 2008, In Brief)
You may also be interested in...
Trial for 5.3 years with more than 25,000 consumers 50 and older pointing to a link between vitamin D and imegta-3s and reducing autoimmune disease isn’t the first with results from VITAL. “It's a big one that we've been watching for a number of years. And it's exciting, some exciting outcomes,” says CRN scientific and regulatory affairs exec Andrea Wong.
In latest study casting doubt on the nutrients' effect on chronic illness, researchers find vitamin D and fish oil ineffective in staving off type 2 diabetics' kidney failure. Editorial also published in JAMA says further research is needed to analyze the nutrients’ possible benefits to diabetics with chronic kidney disease.
Trade group's annual survey shows 77% of US consumers use supplements. It found 12% more men than four years ago report taking vitamin C or D within the past 12 months.